# Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies

## TL;DR

This paper reviews studies showing that ceftolozane/tazobactam is as effective as other antibiotics for treating serious drug-resistant infections.

## Contribution

The study systematically evaluates ceftolozane/tazobactam's efficacy against multidrug-resistant infections in various clinical settings.

## Key findings

- Ceftolozane/tazobactam showed non-inferiority to meropenem in all-cause mortality.
- Clinical cure and microbiological eradication were non-inferior to meropenem or levofloxacin.
- The drug is a viable alternative for treating infections caused by multidrug-resistant pathogens.

## Abstract

Introduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed. Ceftolozane/tazobactam is a treatment option that targets multidrug-resistant pathogens and may offer improved patient outcomes compared to traditional antibiotics that are now often ineffective. Objectives: Our objective was to collate findings from comparative efficacy studies to assess the efficacy of ceftolozane/tazobactam for the indications of complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Methods: Two systematic literature reviews were conducted, including randomized controlled trials comparing ceftolozane/tazobactam with other interventions for complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia indications. The outcomes of interest were mortality, clinical cure and microbiological eradication. Results: Ceftolozane/tazobactam was determined to be non-inferior to comparators for all outcomes of interest. All-cause mortality for ceftolozane/tazobactam displayed non-inferiority to meropenem, with the largest numerical differences in all-cause mortality displayed in susceptible patients, such as those with severe renal impairment. Similarly, the clinical cure and microbiological eradication for ceftolozane/tazobactam demonstrated non-inferiority compared to meropenem or levofloxacin. Conclusions: These reviews support the role of ceftolozane/tazobactam as an alternative option, particularly when MDR pathogens are suspected or documented. Their findings may contribute to the standardization of treatment guidelines, ultimately helping to reduce the clinical and economic burdens associated with these infections.